Why carry out this study?

Carbapenem-non-susceptible (CNS) gram-negative infections (GNIs) continues to grow globally and have very limited treatment options

This study assessed cost and clinical effectiveness of imipenem/cilastatin/relebactam (IMI/REL) in treating confirmed CNS GNIs, compared to colistin plus imipenem (CMS + IMI)

What was learned from the study?

Higher drug acquisition cost for IMI/REL over CMS + IMI may be offset by savings from hospital resource use due to reduced nephrotoxicity risk of IMI/REL

For treatment of confirmed CNS GNIs, IMI/REL could be cost-effective or even cost-saving for the US payers compared to CMS + IMI